Obstructive sleep apnoea and Alzheimer’s disease: In search of shared pathomechanisms by Polsek, D. et al.
Contents lists available at ScienceDirect
Neuroscience and Biobehavioral Reviews
journal homepage: www.elsevier.com/locate/neubiorev
Obstructive sleep apnoea and Alzheimer’s disease: In search of shared
pathomechanisms
D. Polseka,b,1, N. Gildeha,c,1, D. Casha,d, R. Winsky-Sommerere, S.C.R. Williamsd, F. Turkheimerd,
G.D. Leschzinera,c,f, M.J. Morrellg, I. Rosenzweiga,c,⁎
a Sleep and Brain Plasticity Centre, CNS, IoPPN, King’s College London, UK
b Croatian Institute for Brain Research, Medical School, University of Zagreb, Croatia
c Sleep Disorders Centre, Guy’s and St Thomas’ Hospital, London, UK
d Department of Neuroimaging, IoPPN, King’s College London, UK
e Surrey Sleep Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
fDepartment of Neurology, Guy’s and St Thomas’ Hospital, London, UK
g Academic Unit of Sleep and Breathing, National Heart and Lung Institute, Imperial College London, UK and NIHR Respiratory Disease Biomedical Research Unit at the
Royal Brompton and Hareﬁeld NHS Foundation Trust and Imperial College London, UK
A R T I C L E I N F O
Keywords:
Obstructive sleep apnea
Alzheimer’s disease
Neuroinﬂammation
Astrocytes
A B S T R A C T
Alzheimer’s disease (AD) is a signiﬁcant public health concern. The incidence continues to rise, and it is set to be
over one million in the UK by 2025. The processes involved in the pathogenesis of AD have been shown to
overlap with those found in cognitive decline in patients with Obstructive Sleep Apnoea (OSA). Currently, the
standard treatment for OSA is Continuous Positive Airway Pressure. Adherence to treatment can, however, be an
issue, especially in patients with dementia. Also, not all patients respond adequately, necessitating the use of
additional treatments. Based on the body of data, we here suggest that excessive and prolonged neuronal activity
might contribute to genesis and acceleration of both AD and OSA in the absence of appropriately structured
sleep. Further, we argue that external factors, including systemic inﬂammation and obesity, are likely to in-
terfere with immunological processes of the brain, and further promote disease progression. If this hypothesis is
proven in future studies, it could have far-reaching clinical translational implications, as well as implications for
future treatment strategies in OSA.
1. Introduction
Alzheimer’s disease (AD) is one of the most signiﬁcant public health
challenges of the 21st century, aﬀecting an ever increasing number of
people. (Cedernaes et al., 2016; Mander et al., 2016) In the UK, the
number of people with dementia is forecast to increase to over 1 million
by 2025, and there are over 6 million people with dementia in Europe.
(Association, 2016) In the United States, someone develops AD every
66 s. (Association, 2016) The AD worldwide epidemic has been touted
as the only disease among the top 10 causes of death in the developed
world that cannot at present be prevented, cured or even slowed.
(Association, 2016) To date, despite signiﬁcant scientiﬁc eﬀorts, dis-
appointingly little has been achieved in the way of eﬀective prevention
and therapeutic intervention for AD, and the urgency for divergent
thinking on how to tackle this epidemic has been recognized. To that
end, sleep has been proposed as a promising candidate that may serve
as both a biomarker of AD, and as a new potentially therapeutic and
preventative strategy for lowering AD risk. (Dissel et al., 2015; Ju et al.,
2014; Kang et al., 2009; Mander et al., 2016)
In the community setting patients with mild to moderate AD fre-
quently suﬀer with agitated behaviour at sunset. They and their carers
also frequently report insomnia and fragmented sleep during the night,
and excessive sleeping during the daytime, the intensity of which cor-
relates with the severity of dementia. (Moran et al., 2005) Sleep dis-
ruption constitutes a core component of AD, and signature abnormal-
ities of sleep have been shown to emerge well before clinical onset of
AD. (Ju et al., 2014; Yaﬀe et al., 2014) Patients with amnestic mild
cognitive impairment show EEG abnormalities during sleep, including
fewer sleep spindles and reduced slow-wave sleep (SWS). (Ju et al.,
2014; Westerberg et al., 2012) Similar sleep impairments are also
present in older adults that are carriers of the apolipoprotein E (APOE)
ε4 allele. The APOE ε4 allele is the most prominent genetic risk factor
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for late-onset AD, and, perhaps unsurprisingly, also one of the re-
cognized risk factors for developing the second most common sleep
disorder, obstructive sleep apnoea (OSA) (Mander et al., 2016). In OSA,
sleep EEG signature abnormalities analogous to those encountered in
AD have been independently reported (D’Rozario et al., 2016). Of note,
thus far neither the time course of changes in the sleep EEG from pre-
clinical to the clinical stages of dementia, nor its trajectory during the
course of OSA process, have been fully documented or understood. (Ju
et al., 2014)
OSA has long been argued to share an epidemiological overlap
(Fig. 1) and a bidirectional, causal relationship with AD (Cedernaes
et al., 2016; Emamian et al., 2016; Pan and Kastin, 2014). OSA is a
highly prevalent, debilitating chronic multi-system disorder, with
strong links to obesity and older age (Lévy et al., 2015). Recent esti-
mates suggest that up to 30% of men, and 12% of women, between 30
and 70 years of age are aﬀected by OSA. (Peppard et al., 2013) It is
characterized by brief periods of repetitive upper airway occlusion
during sleep, leading to periods of intermittent hypoxia, hyper/hypo-
capnia, signiﬁcant sleep fragmentation (Jordan et al., 2014), oxidative
stress, and a chronic low-grade systemic inﬂammatory state. (Lévy
et al., 2015) Some of the co-morbidities associated with untreated OSA
include hypertension, stroke, diabetes, cardiac arrhythmias, myocardial
infarction, heart failure, kidney disease, cancer and neurocognitive
deﬁcits and depression (Daulatzai, 2015; Gildeh et al., 2016; Lévy et al.,
2015). It has been reported that individuals with OSA may convert to
mild cognitive impairment (MCI) and AD at a younger age. (Osorio
et al., 2015) Conversely, successfully treating OSA has been shown to
delay the age of onset into mild cognitive impairment(Osorio et al.,
2015) and to improve cognitive function in AD(Ancoli-Israel et al.,
2008; Cooke et al., 2009). The results of recent meta-analysis suggest
that patients with AD may have ﬁve times higher risk of presenting with
OSA, compared to cognitively intact individuals of similar age.
(Emamian et al., 2016) It has been further suggested that around 50%
of patients with AD will have experienced OSA at some time after their
initial diagnosis, negatively impacting on its prognosis and the quality
of life. (Emamian et al., 2016)
The etiological roots of mechanisms behind eﬀects of OSA on the
central nervous system (CNS) have been extensively debated over the
years (Gozal, 2013; Rosenzweig et al., 2013b), with some advocating
the importance of disturbed sleep (Lim et al., 2013; Rosenzweig et al.,
2014), and others championing the importance of oxidative stress and
neuroinﬂammation over the former (Lavie, 2015; Rosenzweig et al.,
2015; Yaﬀe et al., 2011). On balance, the consensus in the ﬁeld is that
an intricate interplay of all maladaptive and homeostatic adaptive
processes instigated by OSA plays a part. Depending on the idiosyn-
cratic physiological milieu and the severity, intensity and frequency of
insults, this likely gives rise to OSA’s signature neurological deﬁcits, as
suggested by a number of neuroimaging and cognitive studies to date.
(Kylstra et al., 2013; Rosenzweig et al., 2016; Rosenzweig et al., 2015;
Tahmasian et al., 2016) In this opinion and hypotheses generating re-
view, we build on some of these ﬁndings, and we use some of the most
recent theories to extricate and propose several novel processes that
might act as a shared mechanistic pathway between AD and OSA.
2. Sleep architecture or microstructure disturbances as a shared
pathway in pathogenesis of OSA and AD
Signature changes in the sleep electroencephalographic (EEG) mi-
crostructure in OSA have been shown to include reduced slow wave
activity and sigma power (reduced spindle activity) during non-rapid
eye movement (NREM) sleep, along with slowing of the EEG during
REM sleep (D’Rozario et al., 2016). At the very core of these changes
are intercalated increased discrete events or bursts of increased neu-
ronal activity, closely tied to periods of apneic breathing and associated
EEG arousals, resulting in overall sleep deprivation and fragmentation
of sleep. Sleep fragmentation in OSA has been associated with cognitive
decline in a longitudinal study of patients (Cohen-Zion et al., 2004),
and reported to be the most reliable predictor of episodic memory
deﬁcits in this patient group (Daurat et al., 2008). The seminal role of
sleep in the regulation of CNS amyloid burden, and less conclusively in
the regulation of tau levels in the brain, has recently been compre-
hensively argued (for further discussion of original studies refer to
(Cedernaes et al., 2016; Ju et al., 2014; Mander et al., 2016).
The amyloid cascade hypothesis has been one of the most inﬂuential
theoretical models of AD pathology. (Karran et al., 2011) The hypoth-
esis posits that the imbalance between the production and clearance of
amyloid-β (Aβ) peptide in the brain is the initiating and central event in
AD pathology, ultimately leading to neurodegeneration and dementia.
(Blennow et al., 2006; Karran et al., 2011). In the earliest stage of
preclinical AD, soluble Aβ becomes insoluble and aggregates into
amyloid plaques, leading to a reduction in soluble Aβ42 levels in the
cerebrospinal ﬂuid (CSF) (Blennow et al., 2006) Soluble Aβ in the in-
terstitial ﬂuid (ISF) has been shown to decrease during sleep and to
increase during wakefulness. (Ju et al., 2016) Another hallmark of AD,
tau pathology, has been shown to start early in the disease process in
neurons in the medial temporal lobe, more speciﬁcally in the trans-
entorhinal region, and to spread to the hippocampus and amygdala, and
later to the neocortical association areas (Blennow et al., 2006).
Fig. 1. The schematic representation of
proposed shared mechanisms between
Alzheimer’s Disease (AD) and Obstructive
Sleep Apnoea (OSA) (also refer to the text).
Abbreviations: SWS: slow wave sleep; Aβ:
amyloid-β peptide; APOE ε4: apolipoprotein
E (APOE) ε4; TLR2: Toll-like receptor 2.
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Signiﬁcant correlations between subjective and objective measures of
poor sleep with the severity of cortical Aβ burden, CSF measures of Aβ,
and phosphorylated tau in CSF have been demonstrated in cognitively
normal older adults, MCI and AD patients (Mander et al., 2016). In
animals, the hypothalamic neuropeptide orexin-A has been implicated
in this regulation, but the evidence from human studies has been less
consistent (Cedernaes et al., 2016). Impaired function of orexinergic
neurons has also been reported in patients with OSA, but the underlying
mechanisms have not been fully clariﬁed (Dergacheva et al., 2016). On
the other hand, the orexinergic system was shown to be dysregulated in
AD, where its output and function appeared to be overexpressed along
the progression of the neurodegenerative process (Liguori et al., 2014).
Additionally, disruption of circadian rhythms has been shown to pre-
cede the clinical onset of AD in some patients (Cedernaes et al., 2016).
Similarly, in rodent models, experimentally induced sleep disruption
has been shown to lead to several interlinked processes, otherwise in-
dependently implicated in development and progression of AD: an ac-
cumulation of Aβ and tau pathology, an increase in CNS oxidative
stress, and reduction of the structural and functional integrity of the
blood brain barrier (Cedernaes et al., 2016; Heneka et al., 2015). Of
note, in a Drosophila model of AD-like pathology it has been shown that
experimentally increasing sleep could restore long-term memory (Dissel
et al., 2017). A recent study has shown that neuronally derived proteins
are decreased in the CSF of patients with OSA compared to healthy
controls (Ju et al., 2016). Liguori et al. (2017a, 2017b) also reported
lower CSF Aβ42 concentrations, with higher CSF lactate levels, and
higher t-tau/Aβ42 ratio compared to controls and treated patients.
(Liguori et al., 2017b) It has been proposed that this could be due to
impaired interaction between CSF and ISF in OSA (Ju et al., 2016). For
instance, it is likely that during an obstructive apnea respiratory eﬀort
against a closed airway creates elevated intrathoracic and intracranial
pressure along with a sudden pressure reversal at the end of the apnea,
resulting in repetitive high-pressure ﬂuctuations. These ﬂuctuations
may act to impede the glymphatic ﬂow of metabolites from ISF into CSF
leading to their retention and resulting in higher concentrations of Aβ,
tau and other derived metabolites in the ISF (Ju et al., 2016). Moreover,
in patients with OSA associated chronic hypertension, alongside cere-
bral amyloid angiopathy, can lead to increased stiﬀness of blood vessels
that can further reduce clearance eﬃciency and accelerate amyloid
accumulation in the CNS (Mander et al., 2016).
Whilst the exact role of particular sleep rhythms and stages in any
aspect of AD pathology is uncertain, an increasing body of work sup-
ports the notion that NREM sleep may represent a pivotal pathway
through which the brain manages Aβ levels. An interesting mechanistic
model has emerged whereby slow wave activity (SWA) during NREM
sleep has been described as the EEG indicator of reduced synaptic ac-
tivity, with signiﬁcantly decreased cortical metabolic rates (∼40%)
compared to wakefulness. (Ju et al., 2016; Ju et al., 2014) Given that
synaptic activity results in release of Aβ from neurons, it has been
postulated that SWA leads to decreased production and decreased re-
gional levels of Aβ (Ju et al., 2016; Mander et al., 2016). The amplitude
of diurnal variation in Aβ concentration in healthy young adults has
been estimated to be rather high, approximately around 30% peak-to-
peak, suggesting that sleep patterns could considerably aﬀect levels of
soluble Aβ in ISF in states of chronic sleep disruption, such as OSA or
behaviourally restricted sleep in individuals(Ju et al., 2014). Mander
and colleagues (2016) have also long reasoned that disrupted NREM
SWS and excess wakefulness increase Aβ aggregation, which they have
argued itself impairs NREM SWS, resulting in a vicious cycle accel-
erating AD progression (Mander et al., 2016). Moreover, this group has
also proposed the signature association between the low-frequency
range of NREM SWA below 1 Hz (i.e., slow oscillations) with Aβ ac-
cumulation in the medial prefrontal cortex, one of the earliest sites
known to accumulate Aβ in AD pathology. (Mander et al., 2016) In
addition, another hallmark of AD, early neuroﬁbrillary tangle (NFT)
aggregation in the medial temporal lobe during AD progression has
been linked to relative desynchronization of hippocampal ripples in
rodents, and abnormally long hyperpolarized down-states and impaired
depolarizing up-states during NREM slow oscillations (Mander et al.,
2016). The associations between CSF tau and diminished NREM SWS
have also been reported in clinical studies (Mander et al., 2016). Per-
haps correspondingly, it has been shown that AD patients have fewer
NREM sleep spindles relative to healthy older adults, with the degree of
spindle reduction predicting the severity of memory impairment
(Ancoli-Israel et al., 2008). In the same vein, in OSA patients, altered
spindle activity has also been argued to indicate frontal thalamo-cor-
tical dysfunction (Carvalho et al., 2014). The changes in the micro-
structure of NREM sleep have also been implicated, and their role in-
vestigated in cognitive impairment (Ferini-Strambi et al., 2013; Maestri
et al., 2015). For example, cyclic alternating pattern (CAP), a sponta-
neous and physiological rhythm of NREM sleep, characterized by
electroencephalographic oscillations believed to correspond to a con-
dition of sustained arousal instability (Maestri et al., 2015). CAP rate,
and CAP slow components (A1 index) were reported as decreased in
MCI subjects, and to a greater extent in AD patients, compared to
cognitively intact controls(Maestri et al., 2015).
Although the relationship between NREM disruption and AD pa-
thology is recognised, this link has also been argued to extend to REM
sleep disruption (Mander et al., 2016). One of the proposed functions of
REM sleep is the regulation of emotional reactivity and mood states,
both of which have been shown to be disturbed in AD patients (Mander
et al., 2016). AD patients suﬀer with impaired enhancing eﬀects of
emotion on memory retention, and they express deﬁcits in processing of
complex emotional information (Mander et al., 2016). Furthermore,
major depressive disorder and post-traumatic stress disorder, known to
be linked with OSA, and associated with REM sleep disturbance, have
been both recognized as risk factors for developing of AD (Mander
et al., 2016; Rosenzweig et al., 2015). Additionally, reduced REM sleep
amount, delayed REM sleep onset, and blunted rebound of REM sleep
following selective deprivation have all been demonstrated in patients
with MCI and AD (Mander et al., 2016). Moreover, reductions in the
EEG quality of REM sleep have been proposed as a possible biomarker
that could help discriminate those with AD from cognitively normal
older adults (Hassainia et al., 1997) and REM sleep was recently shown
to be a risk factor to develop dementia(Pase et al., 2017). The selective
degeneration of cholinergic projection neurons within the brainstem
and basal forebrain in AD brains, has been proposed as possible me-
chanism that may underlie this disruption (Blennow et al., 2006;
Mander et al., 2016). In keeping, the degree of cortical Aβ burden has
been shown to correlate with the degree of basal forebrain atrophy, due
to amyloid angiopathy, in healthy older adults, MCI, and AD patients
(Kerbler et al., 2015). Also, Aβ and tau burden have been both im-
plicated in the degeneration of cholinergic neurons projecting from the
basal forebrain to the cortex (Mander et al., 2016). Analogously, in a
recent exploratory transcranial magnetic stimulation (TMS) study, im-
paired cognitive performance in OSA patients have been linked with a
dysfunction of the cholinergic system (Nardone et al., 2016).
Whilst the discussed reciprocal mechanisms behind AD pathology
and sleep disruption might not all be equally implicated in diﬀerent
phenotypes, or indeed stages of OSA, they nonetheless raise some valid
questions and evidently argue novel treatment targets (Castronovo
et al., 2014; Liguori et al., 2017a). After all, the current gold standard
treatment for OSA, i.e. continuous positive airway pressure device
(CPAP), is poorly tolerated by many patients, and the limited im-
provement and refractoriness of neurological deﬁcits to CPAP treatment
have been long recognised (Castronovo et al., 2014; Rosenzweig et al.,
2015). In the future, depending on the sub-phenotype of OSA and its
symptom constellation a personalized medical approach could warrant
that alternative treatments and interventions in patients with OSA are
used in combination with CPAP or other interventions and lifestyle
factors. For instance, in dysphoric and anxious OSA patients with pre-
dominant cognitive problems, cholinesterase inhibitors might be
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prescribed. Cholinesterase inhibitors have been shown to increase REM
sleep quality and duration (Mander et al., 2016), and they might ar-
guably help with memory, mood and emotional symptoms in AD and
OSA patients. Conversely, therapeutic interventions that have been
shown to restore NREM SWS (e.g. auditory closed-loop stimulation
(Ngo et al., 2013) or transcranial current stimulation) might be used as
a preventative measure to reduce AD risk in younger patients, or in
high-vulnerability populations, such as patients with Down’s syndrome
or individuals carrying the ApoE ε4 allele with marked sleep deﬁcits
(Mander et al., 2016).
3. Neurogenic neuroinﬂammation as a shared pathway in
pathogenesis of OSA and AD
Remarkably, taken together, the body of evidence appears to
strongly argue for prolonged wakefulness, or rather the excessive
neuronal synaptic activity, as “unus mundus”, the most unifying feature
underlying the link between sleep and AD pathology. Aside from the
sophisticated complexities of sleep-related eﬀects, the evidence would
suggest that it is the excessive neuronal synaptic activity itself that is
suﬃcient to set in motion the maladaptive positive-feedback-forward
loop through increased production of Aβ, higher neurometabolic rate
and oxidative stress, which can then further interfere with sleep pro-
cesses, and ultimately lead to accelerated AD pathophysiological pro-
gression(Mander et al., 2016). Some indirect support for this notion can
be drawn from neuroimaging studies, where increased Aβ deposition
has been shown to occur preferentially in multimodal brain regions
corresponding to a default mode network and including the posterior
cingulate cortex, parahippocampal gyrus and medial frontal cortex
(Jagust and Mormino, 2011). These regions show continuous levels of
heightened activation and plasticity across the lifespan, which could
underlie their vulnerability (Jagust and Mormino, 2011; Ju et al.,
2014). Moreover, neuroimaging studies of subjects with genetic pre-
dispositions to AD have also been consistent with these ﬁndings, sug-
gesting a mechanism whereby neural eﬃciency or cognitive reserve
may diminish Aβ deposition (Jagust and Mormino, 2011). In further
support, it has been recently proposed that inﬂammatory responses in
the CNS, including orchestrated actions of immune cells, vascular cells
and neurons can be triggered by the increased neuronal activity. The
technical term ‘neurogenic neuroinﬂammation' has been suggested
(refer to (Xanthos and Sandkuhler, 2014).
3.1. Neurogenic neuroinﬂammation and the multipartite synapse
In comparison to the inﬂammatory responses to various insults that
are readily induced in regenerating peripheral tissues, the relatively
mild inﬂammatory tissue reactions in the CNS reﬂect lower re-
generative capacity of neurons (Xanthos and Sandkuhler, 2014). It has
been proposed that under normal conditions neurogenic neuroin-
ﬂammation acts to maintain homeostasis and enables the CNS to cope
with enhanced metabolic demands (Xanthos and Sandkuhler, 2014). It
has been suggested that it may also modulate the computational power
and plasticity in neuronal networks (Xanthos and Sandkuhler, 2014).
This concept is not new and the seminal body of work by Attwell and
colleagues, and other groups, supports the crucial role for multi-
directional synapse cross-talks between astrocytes, neurons, glia and
vascular smooth cells as powerful regulators of neuronal spiking, sy-
naptic plasticity and brain blood ﬂow (Bazargani and Attwell, 2016).
Hence, it comes as no surprise that neuroinﬂammation has also been
increasingly argued as a principal treatment target in people with AD
(Heneka et al., 2015), and more recently in OSA (Daulatzai, 2015;
Lavie, 2015). This has been further supported by the results of genome-
wide analyses, which have shown that several genes that increase the
risk for sporadic AD encode factors that regulate glial clearance of
misfolded proteins and the inﬂammatory reaction (Heneka et al.,
2015). Ageing brains of OSA patients in particular may provide a milieu
for a chronic longitudinal priming of microglia, the resident mono-
nuclear phagocytes, to various activators, such as chronic vascular
changes, including cerebrovascular dysregulation and cerebral micro-
infarcts, local ischaemia, chronic exposure to Aβ, neuronal debris, at
times of increasing imbalance between pro-oxidant and anti-oxidant
physiological systems of the body(Lavie, 2015). Various exogenous and
endogenous factors have also been speculated to further modify the
innate immune response induced by Aβ-exposed microglia (Heneka
et al., 2015). Apart from disturbed sleep, amongst other en-
vironmentally modiﬁable risk factors, systemic inﬂammation and obe-
sity have been shown to aﬀect risk through an increase in sustained
neuroinﬂammatory drive (for further discussion and list of original
studies refer to (Heneka et al., 2015)). Notably, co-morbid obesity has
been linked in patients to increased propensity to acquire infections
leading to systemic infection. (Heneka et al., 2015) Obesity-associated
reduced gut microbial diversity has been associated with increased
concentrations of proinﬂammatory markers in peripheral blood
(Heneka et al., 2015). Also, white adipocyte tissue itself has been shown
to have a high percentage of activated macrophages, a rich source of
proinﬂammatory cytokines. (Heneka et al., 2015) Moreover, in a rodent
model, obesity-associated type 2 diabetes has been reported to accel-
erate memory dysfunction and neuroinﬂammation. (Heneka et al.,
2015)
Microglia and astrocytes have been shown to release cytokines, in-
terleukins, nitric oxide (NO), and other potentially cytotoxic molecules
after exposure to Aβ, thereby exacerbating the neuroinﬂammatory re-
sponse (Heneka et al., 2015). Logic would dictate that part of any
homeostatic drive during inﬂammatory processes would have to in-
clude increased clearance of byproducts of this sustained high neuro-
metabolic rate. Sleep’s role in synaptic homeostasis (Cirelli and Tononi,
2015) has long been argued for, and a body of evidence also suggest
that the clearance of neurometabolites predominantly occurs during
sleep (Ju et al., 2014). The clearance of Aβ has been shown to depend
on local degradation by a wide range of proteases, phagocytosis by glial
cells, egress across the BBB, reabsorption through the CSF(Cedernaes
et al., 2016), and most recently it has shown to occur via glymphatic
system during sleep(Xie et al., 2013). Dysregulated microglia has also
been recently shown to contribute to spread of tau pathology via sy-
naptic and non-synaptic transmission, including via exocytosing mi-
crovesicles such as exosomes (Asai et al., 2015).
3.2. Multipartite synapse at the core of pathological changes in AD and OSA
and its role in clearance of Aβ and tau pathology
AD has been associated with distinct inﬂammatory, functional, and
morphological multipartite synapse alterations including regional
changes in cerebral blood vessels and perivascular glia and neurons (the
neurovascular unit) (see Fig. 2A) (Heneka et al., 2015). These early-
onset and progressive changes, which are induced by combined eﬀects
of soluble Aβ oligomers and vascular Aβ deposits, ultimately lead to
decreased cerebral blood ﬂow and impaired functional hyperaemia (ie,
the ability of local blood ﬂow to increase in response to neuronal ac-
tivation). From a clinical perspective it is hence important to note that
pharmacologically modulating inﬂammatory signalling pathways sys-
temically or regionally (but not cell speciﬁcally) may inadvertently
result in complex synergistic and/or antagonist interactions with un-
predictable overall results(Xanthos and Sandkuhler, 2014). For in-
stance, it is possible that previously reported slowing of wakeful EEG in
both AD and OSA patient groups (D’Rozario et al., 2016) is not solely an
epiphenomenon of underlying CNS changes, but that they in a fact
present as a result of a still poorly understood homeostatic mechanism,
which acts to decrease excessive neuronal and neurometabolic activity
over the periods of wake to counteract insuﬃcient periods of senes-
cence during sleep (Ju et al., 2014; D’Rozario et al., 2016). Arguably
this would not be that dissimilar to accepted exogenous iatrogenic in-
tervention of placing a patient with an ongoing refractory status
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Fig. 2. Proposed eﬀects of disturbed sleep and altered neuronal activity at the level of multipartite synapse (A) (adapted from(Fellin et al., 2006; Xanthos and Sandkuhler, 2014).
Increased clearance of metabolites has been postulated to occur during sleep, due to a low noradrenergic tone and decrease in astrocyte volume, resulting in increased extracellular space
and increased glymphatic ﬂow(B). (for in depth explanation refer to the main text). Abbreviations: NA: noradrenaline; ECS: extracellular space; Aβ: amyloid-β peptide; CSF: cerebrospinal
ﬂuid; ISF; interstitial ﬂuid.
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epilepticus under the general anesthesia. It perhaps follows, that at least
theoretically, any forced non-personalised intervention, such as may
occur during indiscriminately used CPAP intervention, might at least
initially counteract adaptive aspects of inﬂammation before resolving
the cause of the inﬂammatory process. This concept is yet to be con-
ﬁrmed in future prospective studies, but it may as such signiﬁcantly
change our approach to sleep management in OSA patients.
Another potentially interesting treatment target for AD would have
to involve the regulation of the CNS extracellular space (Fig. 2B). The
extracellular space (ECS) is possibly best described as an interconnected
channel mesh that allows diﬀusion-mediated transport of signalling
molecules, metabolites, and drugs (Sherpa et al., 2016). Astrocytes and
their morphology have been increasingly implicated in regulation of
this space under normal and pathological conditions. For instance, as-
trocytic swelling under conditions of ischaemia or inﬂammation in-
creases so called the ‘dead-space domains’ in the ECS, which have been
demonstrated even after recovery of the acute swelling(Sherpa et al.,
2014). The possible clinical implication for AD and OSA patients would
be that inﬂammation driven repeated hypoxic or hypotonic stress may
with time lead to increasing refractory tortuosity of the ECS whereby
toxic metabolites such as Aβ oligomers are trapped. Relatedly, it has
been shown that the ECS decreases in part through an increase in as-
trocytic volume following β2 adrenergic receptor (β2AR) activation.
This is of relevance as it implies close noradrenergic regulation of sy-
naptic availability and extracellular concentration of neurotransmitters
and neuromodulators that can help facilitate neuronal interactions,
especially during wakefulness (Sherpa et al., 2016). Conversely, astro-
cytes have also been proposed to play an important role in clearance of
soluble Aβ from the parenchyma by paravascular drainage, the recently
described glymphatic system (Jessen et al., 2015). It has been suggested
that this pathway depends on the astrocytic water channel aquaporin 4
(Jessen et al., 2015; Mander et al., 2016), although this notion was
recently challenged(Smith et al., 2017). Whilst its function in human
metabolic clearance is yet to be comprehensively demonstrated, in-
direct support has been provided by several recent neuroimaging stu-
dies (Bernardi et al., 2016; Cedernaes et al., 2016). In rodents, a 60%
increase in the ECS has been shown during sleep (Xie et al., 2013), as
compared with the space found during wakefulness, and sleep was
found to increase the convective ﬂow of ISF from the para-arterial to
the para-venous space resulting in a doubling of the rate of Aβ removal
(Cedernaes et al., 2016; Mander et al., 2016). Moreover, these eﬀects
were furthermore mimicked by infusion of noradrenergic receptor an-
tagonists, suggesting that low adrenergic input is required for this
convective clearance to occur (Xie et al., 2013).
Based on these ﬁndings it has been proposed that locus coeruleus
(LC) quiescence during sleep may act as the main driver of metabolite
clearance by lowering the adrenergic tone (Mander et al., 2016). LC,
located at the dorsal part of the brain stem, is the main source of nor-
adrenaline (NA) in the brain. The LC neurons project throughout the
brain, where NA is released via axonal varicosities via volume trans-
mission. The reciprocal monosynaptic pathways between the mPFC and
LC have been previously demonstrated, and complex excitatory and
inhibitory eﬀects on cortical and subcortical cells, depending on con-
centration of the NA and on receptor distribution and aﬃnity in the
target region have been described (Atzori et al., 2016). Of relevance to
AD pathology, in addition to its role as a neurotransmitter, NA has
potent anti-inﬂammatory, anti-oxidative, neurotrophic, and neuropro-
tective actions. (Heneka et al., 2015) and LC-NA release has been
postulated as a powerful central regulator of CNS spatio-temporal ac-
tivation and energy expenditure (refer to (Atzori et al., 2016)). The
number of cells in the LC, and concentration of NA in the brain, de-
crease during normal ageing, although more pronounced cell loss has
been demonstrated in patients with AD. (Heneka et al., 2015) Thus,
early degeneration of the LC and subsequent loss of NA-mediated in-
nervation could substantially promote the inﬂammatory response to
any stimulus, including Aβ. Similar degeneration has been observed in
animal models of OSA (Zhu et al., 2007). However in patients with OSA
due to technical limitations of brain stem and sleep imaging (Otte et al.,
2016), no conclusive data are yet available. Experimental loss of NA has
been shown to compromise microglial migration and Aβ phagocytosis
in vivo, suggesting that a loss of NA tone increases not only inﬂamma-
tion, but also Aβ deposition (Heneka et al., 2015). We suggest that the
importance of LC ﬁring in AD and OSA pathology is hence twofold: its
quiescence and low NA tone have been argued crucial for eﬀective
sleep-driven glymphatic clearance of metabolites, whilst its activity
during wakefulness might regulate the ECS space, contribute to CNS
spatio-temporal activation and consciousness states, and regulate en-
ergy expenditure (Atzori et al., 2016; Sherpa et al., 2014). Of note LC-
NA system ﬁring has been shown during NREM EEG slow oscillations,
correlating with Down-to-Up state transition (Eschenko et al., 2012).
Arguably, LC ﬁring at the times of the cortico-hippocampal neuronal
replay might suggest a novel and intriguing role for the LC in sleep-
dependent memory consolidation (Eschenko et al., 2012). This ﬁnding
might also be of particular importance for OSA pathology, as any such
arousal-driven activation of LC during the night might inappropriately
hijack its role with serious consequences for sleep-mediated memory
consolidation and plasticity (Rosenzweig et al., 2016; Twigg et al.,
2010). Moreover, on a more mechanistic level, LC-NA system ﬁring
during NREM EEG slow oscillations might also have a pure mechanistic
pulsatile eﬀect through astrocytes-driven changes in ECS, providing a
more eﬃcient clearance at times of synchronised neuronal activity
(Fig. 2). It would follow, that in OSA and AD, any such mechanism
would also be misappropriated and impaired with serious con-
sequences. Future electrophysiological and neuroimaging studies
should help elucidate these intriguing theoretical possibilities.
Finally, the functional connection of AD and OSA with endogenous
neurogenesis remains a lingering question in the ﬁeld. Neurogenesis –
the formation of new neurons in the adult brain – is considered to be
one of the mechanisms by which the brain maintains its lifelong plas-
ticity in response to extrinsic and intrinsic changes. In OSA hippo-
campal hypertrophy in a cohort of patients with predominantly mild
OSA has been demonstrated, whereby it has been argued that altered
endogenous neuroglia genesis might play a part in the homeostatic
adaptive process to a mild injury in some patients. (Rosenzweig et al.,
2013a) One of the new promising therapeutic avenues for treatment of
AD pathology might be via enhancing endogenous neurogenesis and
promotion of compensatory role for newborn neurons in dementia. In
keeping, ﬁndings from number of animal and clinical studies, mainly
from the previous non-English speaking (e.g. previous USSR) countries,
have suggested that intermittent hypoxia might have bidirectional re-
lationship with endogenous neurogenesis as a part of the adaptive
homeostatic ischaemic pre/postconditioning processes (Mateika and
Komnenov, 2017). Perhaps relatedly, Ekonomou and colleagues (2015)
recently reported that severe AD pathology impaired the production of
new neurons, and that there was a signiﬁcant positive correlation be-
tween the cell numbers of activated microglia and those of the newly
generated neurons (Ekonomou et al., 2015). It has been previously
proposed that microglia sense signals from the surrounding environ-
ment and have regulatory eﬀects, both proneurogenic and anti-
neurogenic, on adult neurogenesis (Heneka et al., 2015; Rolls et al.,
2007). In support, microglial Toll-like receptor 2 (TLR2) deﬁciency in
mice has been shown to impair hippocampal neurogenesis(Rolls et al.,
2007). TLR2 expression and activity has also been shown increased on
monocytes of patients with OSA. (Chen et al., 2015) It arguably follows
that any potential future AD or OSA neurogenic therapy would likely
need to target neuroinﬂammation simultaneously to be eﬀective.
4. Conclusion and future directions
The increasing body of data suggests that excessive and prolonged
neuronal activity in the absence of appropriately structured sleep and
periods of neuronal quiescence might contribute to genesis and
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acceleration of the neurodegenerative process in patients with AD. If
this hypothesis is borne out in future studies, it could have far-reaching
clinical translational implications, as well as implications for future
treatment strategies in OSA. Currently, the standard treatment for OSA
is CPAP treatment, which has been shown eﬀective in slowing the
cognitive decline in comorbid OSA and AD (Troussiere et al., 2014).
However, the adherence to treatment can be an issue, especially in
patients with dementia, and not all patients respond adequately, ne-
cessitating the use of additional treatments. In addition, external fac-
tors, including systemic inﬂammation and obesity, are likely to inter-
fere with immunological processes of the brain and further promote
disease progression. Modulation of risk factors and targeting of these
immune mechanisms could lead to future therapeutic or preventive
strategies for both co-morbidities, OSA and AD. For example, in certain
individuals, by treating the neuroinﬂammation early (e.g. via anti-in-
ﬂammatory agents) along with the CPAP treatment, even prior to the
development of any neurocognitive pathology, the genesis, or slowing
of subsequent pathology and later dementia might be possible. In ad-
dition, the possible role for early adaptive microglial activation to in-
termittent hypoxia in activation and promotion of endogenous neuro-
genesis could be an attractive therapeutic target. Similarly, by targeting
pronounced sleep fragmentation and enhancing SWA (e.g. by non-in-
vasive stimulation), Aβ production and clearance might be inﬂuenced.
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